4-Chlorbenzoyl Berbamine, A Novel Derivative Of The Natural Product Berbamine, Potently Inhibits The Growth Of Human Myeloma Cells By Modulating The Nf-B And Jnk Signalling Pathways

Multiple myeloma (MM) remains incurable despite the development and the use of new agents. In our studies, we found that 4-chlorbenzoyl berbamine (BBMD9), a novel synthetic derivative of berbamine, inhibited the proliferation of MM cells in dose- and time-dependent manners. Flow cytometric (FCM) analysis revealed that MM cells were arrested in the G1 phase and that apoptotic cells increased in a time-dependent manner. Moreover, the BBMD9 treatment downregulated IKK and IKK, inhibited p-IB, and blocked p65 nuclear localization. Consistently, NF-B downstream targets, such as cyclinD1 and survivin, were also reduced. In addition, BBMD9 phosphorylated the activity of JNK and c-Jun.